• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Baseline characteristics of patients predicting suitability for rapid naltrexone induction.预测快速纳曲酮诱导适用性的患者基线特征。
Am J Addict. 2015 Apr;24(3):258-264. doi: 10.1111/ajad.12180.
2
Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.失业的海洛因依赖成年人中使用长效纳曲酮的预测因素。
J Subst Abuse Treat. 2018 Feb;85:38-44. doi: 10.1016/j.jsat.2017.04.012. Epub 2017 Apr 20.
3
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.长效注射用纳曲酮诱导:纳曲酮与丁丙诺啡用于门诊阿片类药物脱毒的随机试验
Am J Psychiatry. 2017 May 1;174(5):459-467. doi: 10.1176/appi.ajp.2016.16050548. Epub 2017 Jan 10.
4
A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder.为期一周的门诊 XR-纳曲酮诱导治疗,用于治疗阿片类药物使用障碍患者。
Am J Drug Alcohol Abuse. 2020 May 3;46(3):289-296. doi: 10.1080/00952990.2019.1700265. Epub 2019 Dec 20.
5
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.门诊患者向阿片类药物使用障碍患者过渡使用长效纳曲酮注射剂:一项 3 期随机试验。
Drug Alcohol Depend. 2018 Jun 1;187:171-178. doi: 10.1016/j.drugalcdep.2018.02.023. Epub 2018 Apr 10.
6
Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.麻醉辅助与丁丙诺啡或可乐定辅助的海洛因脱毒及纳曲酮诱导:一项随机试验
JAMA. 2005 Aug 24;294(8):903-13. doi: 10.1001/jama.294.8.903.
7
Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.接受口服纳曲酮(无论是否单次注射纳曲酮)治疗的患者的阿片类药物使用情况及退出治疗情况。
Drug Alcohol Depend. 2015 Feb 1;147:122-9. doi: 10.1016/j.drugalcdep.2014.11.028. Epub 2014 Dec 9.
8
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.与临床试验中开始使用 XR-纳曲酮治疗阿片类药物使用障碍相关的患者特征。
Drug Alcohol Depend. 2022 Apr 1;233:109343. doi: 10.1016/j.drugalcdep.2022.109343. Epub 2022 Feb 2.
9
Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up.注射用长效纳曲酮(XR-NTX)治疗阿片类物质依赖对住院康复结局及早期随访的影响。
Am J Addict. 2015 Apr;24(3):265-270. doi: 10.1111/ajad.12182. Epub 2015 Feb 4.
10
Extended-release injectable naltrexone for opioid use disorder: a systematic review.长效注射用纳曲酮治疗阿片类药物使用障碍:系统评价。
Addiction. 2018 Jul;113(7):1188-1209. doi: 10.1111/add.14180. Epub 2018 Mar 24.

引用本文的文献

1
High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study.长效纳曲酮对阿片类物质使用障碍患者的高诱导率:一项挪威自然主义研究的经验
Addict Sci Clin Pract. 2025 Jun 16;20(1):50. doi: 10.1186/s13722-025-00576-9.
2
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.在住院环境中,寻求从丁丙诺啡向纳曲酮缓释片转换的阿片类使用障碍个体的特征和治疗偏好。
Am J Addict. 2022 Mar;31(2):142-147. doi: 10.1111/ajad.13264. Epub 2022 Feb 9.
3
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.与临床试验中开始使用 XR-纳曲酮治疗阿片类药物使用障碍相关的患者特征。
Drug Alcohol Depend. 2022 Apr 1;233:109343. doi: 10.1016/j.drugalcdep.2022.109343. Epub 2022 Feb 2.
4
A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.一项比较缓释注射混悬剂和口服纳曲酮,均联合行为疗法,用于治疗阿片类药物使用障碍的随机试验。
Am J Psychiatry. 2019 Feb 1;176(2):129-137. doi: 10.1176/appi.ajp.2018.17070732. Epub 2018 Oct 19.
5
Extended-release injectable naltrexone for opioid use disorder: a systematic review.长效注射用纳曲酮治疗阿片类药物使用障碍:系统评价。
Addiction. 2018 Jul;113(7):1188-1209. doi: 10.1111/add.14180. Epub 2018 Mar 24.
6
Opioid antagonists with minimal sedation for opioid withdrawal.用于阿片类药物戒断且镇静作用极小的阿片类拮抗剂。
Cochrane Database Syst Rev. 2017 May 29;5(5):CD002021. doi: 10.1002/14651858.CD002021.pub4.
7
Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.失业的海洛因依赖成年人中使用长效纳曲酮的预测因素。
J Subst Abuse Treat. 2018 Feb;85:38-44. doi: 10.1016/j.jsat.2017.04.012. Epub 2017 Apr 20.
8
Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.接受长效纳曲酮(XR-NTX)治疗阿片类物质使用障碍的社区患者的长期随访研究。
Am J Addict. 2017 Jun;26(4):319-325. doi: 10.1111/ajad.12527. Epub 2017 Mar 22.
9
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.长效注射用纳曲酮诱导:纳曲酮与丁丙诺啡用于门诊阿片类药物脱毒的随机试验
Am J Psychiatry. 2017 May 1;174(5):459-467. doi: 10.1176/appi.ajp.2016.16050548. Epub 2017 Jan 10.
10
Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.有效性试验设计中的伦理与临床安全性考量:丁丙诺啡与纳曲酮治疗阿片类药物依赖的比较
Contemp Clin Trials. 2016 Nov;51:34-43. doi: 10.1016/j.cct.2016.09.006. Epub 2016 Sep 28.

本文引用的文献

1
A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.一项关于美金刚作为长效注射用纳曲酮治疗阿片类物质依赖辅助用药的安慰剂对照试验。
J Subst Abuse Treat. 2014 May-Jun;46(5):546-52. doi: 10.1016/j.jsat.2014.01.005. Epub 2014 Jan 17.
2
A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.一项针对主要处方类阿片滥用者丁丙诺啡减量持续时间的随机、双盲评估。
JAMA Psychiatry. 2013 Dec;70(12):1347-54. doi: 10.1001/jamapsychiatry.2013.2216.
3
Treatment outcome predictors in flexible dose-duration methadone detoxification program.灵活剂量-时间美沙酮脱毒方案的治疗结果预测因子。
Arch Iran Med. 2013 Oct;16(10):599-601.
4
A call for evidence-based medical treatment of opioid dependence in the United States and Canada.呼吁在美国和加拿大进行基于证据的阿片类药物依赖治疗。
Health Aff (Millwood). 2013 Aug;32(8):1462-9. doi: 10.1377/hlthaff.2012.0846.
5
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.注射用延长释放型纳曲酮(XR-NTX)治疗阿片类药物依赖:长期安全性和有效性。
Addiction. 2013 Sep;108(9):1628-37. doi: 10.1111/add.12208. Epub 2013 May 24.
6
Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.与丁丙诺啡/纳洛酮治疗处方类阿片依赖治疗结局相关的患者特征:一项多中心研究的结果。
Drug Alcohol Depend. 2013 Jul 1;131(1-2):112-8. doi: 10.1016/j.drugalcdep.2012.12.010. Epub 2013 Jan 18.
7
Predictors of outcome after short-term stabilization with buprenorphine.短期丁丙诺啡稳定治疗后的结局预测因素。
J Subst Abuse Treat. 2013 Mar;44(3):336-42. doi: 10.1016/j.jsat.2012.08.016. Epub 2012 Sep 26.
8
Maintenance of reinforcement to address the chronic nature of drug addiction.强化维持治疗以应对药物成瘾的慢性特征。
Prev Med. 2012 Nov;55 Suppl(Suppl):S46-53. doi: 10.1016/j.ypmed.2012.03.013. Epub 2012 Jun 5.
9
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.阿片类药物脱毒和纳曲酮诱导策略:临床实践建议。
Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. doi: 10.3109/00952990.2011.653426. Epub 2012 Mar 12.
10
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.在短期和长期丁丙诺啡-纳洛酮治疗处方阿片类药物依赖期间的辅助咨询:一项两阶段随机对照试验。
Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7.

预测快速纳曲酮诱导适用性的患者基线特征。

Baseline characteristics of patients predicting suitability for rapid naltrexone induction.

作者信息

Mogali Shanthi, Khan Nabil A, Drill Esther S, Pavlicova Martina, Sullivan Maria A, Nunes Edward, Bisaga Adam

机构信息

Division of Substance Abuse, New York State Psychiatric Institute, New York, NY.

Department of Biostatistics, Columbia University, New York, NY.

出版信息

Am J Addict. 2015 Apr;24(3):258-264. doi: 10.1111/ajad.12180.

DOI:10.1111/ajad.12180
PMID:25907815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4496800/
Abstract

BACKGROUND AND OBJECTIVES

Extended-release (XR) injection naltrexone has proved promising in the treatment of opioid dependence. Induction onto naltrexone is often accomplished with a procedure known as rapid naltrexone induction. The purpose of this study was to evaluate pre-treatment patient characteristics as predictors of successful completion of a rapid naltrexone induction procedure prior to XR naltrexone treatment.

METHODS

A chart review of 150 consecutive research participants (N = 84 completers and N = 66 non-completers) undergoing a rapid naltrexone induction with the buprenorphone-clonidine procedure were compared on a number of baseline demographic, clinical and psychosocial factors. Logistic regression was used to identify client characteristics that may predict successful initiation of naltrexone after a rapid induction-detoxification.

RESULTS

Patients who failed to successfully initiate naltrexone were younger (AOR: 1.040, CI: 1.006, 1.075), and using 10 or more bags of heroin (or equivalent) per day (AOR: 0.881, CI: 0.820, 0.946). Drug use other than opioids was also predictive of failure to initiate naltrexone in simple bivariate analyses, but was no longer significant when controlling for age and opioid use level.

CONCLUSIONS

Younger age, and indicators of greater substance dependence severity (more current opioid use, other substance use) predict difficulty completing a rapid naltrexone induction procedure. Such patients might require a longer period of stabilization and/or more gradual detoxification prior to initiating naltrexone.

SCIENTIFIC SIGNIFICANCE

Our study findings identify specific characteristics of patients who responded positively to rapid naltrexone induction.

摘要

背景与目的

缓释注射用纳曲酮已被证明在治疗阿片类药物依赖方面很有前景。纳曲酮的诱导治疗通常通过一种称为快速纳曲酮诱导的程序来完成。本研究的目的是评估治疗前患者的特征,作为在接受缓释纳曲酮治疗之前快速纳曲酮诱导程序成功完成的预测指标。

方法

对150名连续的研究参与者(84名完成者和66名未完成者)进行图表回顾,这些参与者采用丁丙诺啡-可乐定程序进行快速纳曲酮诱导,并比较了一些基线人口统计学、临床和心理社会因素。使用逻辑回归来确定可能预测快速诱导脱毒后纳曲酮成功启动的患者特征。

结果

未能成功启动纳曲酮的患者年龄较小(调整后比值比[AOR]:1.040,置信区间[CI]:1.006,1.075),且每天使用10袋或更多海洛因(或等效物)(AOR:0.881,CI:0.820,0.946)。在简单的双变量分析中,除阿片类药物外的其他药物使用也可预测纳曲酮启动失败,但在控制年龄和阿片类药物使用水平后不再显著。

结论

年龄较小以及物质依赖严重程度较高(当前阿片类药物使用更多、其他物质使用)的指标预示着快速纳曲酮诱导程序难以完成。这类患者在启动纳曲酮之前可能需要更长时间的稳定期和/或更缓慢的脱毒过程。

科学意义

我们的研究结果确定了对快速纳曲酮诱导有积极反应患者的具体特征。